The trial, ACT-OA, is a phase II, randomized, double-blind, placebo-controlled trial including 90 patients. It aims to evaluate the efficacy and safety of Cytori Cell Therapy — the company’s autologous adipose derived therapy.
The patient was treated by Peter Hanson, MD, medical director of orthopedic surgery at Sharp Grossmont Hospital in San Diego.
More articles on devices:
Medtronic’s VERTEX Reconstruction System receives FDA approval for expanded indications
Sonoma Orthopedic Products receives FDA clearance for FibuLock Nail
Argus raises Integra Lifesciences’ price target to $61
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
